Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Apr 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-04-23

Reporting Person: Deschatelets Pascal (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-23	Common Stock	M	6250	$2.67	Acquired	871337	Direct
2021-04-23	Common Stock	S	6250	$46.13	Disposed	865087	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-23	Stock Option (Right to Buy)	$2.67	M	6250	Disposed	2023-12-05	Common Stock (6250)	Direct

Footnotes

F1: This is a scheduled exercise from 10B5-1 trading plan.

F2: This stock option was granted on 12/5/2013 and is fully vested.